Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680885 · ClinicalTrials.gov registry record · Early Phase 1
Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness
A Early Phase 1 study of ADHD and Controls, sponsored by PhenoSolve.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03680885: Completed Early Phase 1 study of ADHD and Controls, sponsored by PhenoSolve.
NCT03680885 is a Early Phase 1 study of ADHD and Controls that has completed, run by PhenoSolve. The registered enrollment target is 20 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680885, a Early Phase 1 study of ADHD and Controls, has completed, sponsored by PhenoSolve.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine
Primary Outcome
The subject is blinded to the tastant and gel identities. The 3 tastants are tested in randomized order. After application of lidocaine gel or placebo to the tongue, and a wait of 2 minutes, the subject's tongue is rubbed with a swab that has been wet with the tastant on the subject's tongue. The subject is asked to identify the taste (e.g., sweet). Then, on a 5-point scale (0-4, ranging from none to very intense) they are asked to rate the intensity of the taste. The process is repeated for
Interventions
- DRUG Placebo
- DRUG Lidocaine gel
- DRUG Injected lidocaine
Study Locations (1)
New York
- Jacobi Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2020-03-30 |
| Phase | Early Phase 1 |
What the finished NCT03680885 record still lists
NCT03680885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with ADHD appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03680885 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03680885 about?
NCT03680885 is a clinical study titled "Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness". This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine
What is the current status of trial NCT03680885?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-01. Estimated completion is 2020-03-30.
What conditions does trial NCT03680885 study?
This clinical trial studies the following conditions: ADHD, Controls.
What interventions are being tested in trial NCT03680885?
The interventions under investigation include: Placebo (DRUG), Lidocaine gel (DRUG), Injected lidocaine (DRUG).
Who is sponsoring clinical trial NCT03680885?
This trial is sponsored by PhenoSolve, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680885 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03680885's enrollment target sits among peer trials
20 70th of 75 higher than 5 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Evaluating Treatment of ADHD in Children with Down Syndrome
RECRUITING · Phase 4
-
Fidgeting and Attentional and Emotional Regulation in ADHD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI